ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1890

Methotrexate Adverse Events in a Randomized Double-Blind Placebo-Controlled Trial:Results from the Cardiovascular Inflammation Reduction Trial (CIRT)

Daniel Solomon1, Robert Glynn 2, Elizabeth Karlson 3, Fengxin Lu 3, Cassandra Corrigan 3, Joshua Colls 3, Chang Xu 3, Jean MacFadyen 3, Medha Barbhaiya 4, Nancy Berliner 3, Paul Dellaripa 3, Brendan Everett 3, Sara Hammond 3, Meredith Murray 3, Deepak Rao 3, Susan Ritter 5, Anna Rutherford 5, Jeffrey Sparks 3, Jacklyn Stratton 5, Dong Suh 3, Sara K. Tedeschi 6, Kathleen Vanni 3, Nina Paynter 5 and Paul Ridker 5, 1Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, 2Harvard Medical School - Boston, MA, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 5Brigham and Women's Hospital, Boston, 6Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: drug safety, drug safety monitoring and randomized trials, Epidemiologic methods, methotrexate (MTX)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Session Title: 4M117: RA – Treatments III: Cardiovascular Disease & Readmissions (1890–1895)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Prior observational studies have estimated the risk of adverse events with low dose methotrexate (MTX). However, prior randomized controlled trials (RCT) were too small to precisely estimate the risk of MTX-related adverse events (AEs). We investigated the risk of AEs in patients without rheumatic disease using MTX compared with placebo.

Methods: We conducted pre-specified secondary analyses of the CIRT randomized controlled trial (Ridker et al, NEJM, 2019). The trial was conducted in N. America among adults with known cardiovascular disease and diabetes or metabolic syndrome. Subjects were randomly allocated to low dose MTX (maximum 20mg/week) or placebo. All subjects received folic acid 1mg for six days/week. The “AEs of interest” were adjudicated blinded to study drug assignment; they included gastrointestinal (hepatic or other), pulmonary (COPD, bronchitis, or pneumonitis), infectious, hematologic (bleeding or cytopenias), malignant, mucocutaneous (skin, alopecia or oral lesions), renal (acute kidney insufficiency or nephrolithiasis), neuropsychiatric, and musculoskeletal. The frequency and relative rates of the specific AEs of interest, laboratory AEs (AST, ALT, and CBC) as well as all reported AEs were compared across treatment arms in intention to treat analyses.  We estimated the hazard ratios (HR) using Cox proportional hazards regression. Skin cancers were further examined by sub-type using the same methods.

Results: 6,158 patients were enrolled and 4,786 randomized after a 5-8 week active run-in period and followed for a mean of 27 months on a median dosage of 16mg. Of the 2,391 subjects randomized to MTX, 2,104 (84.5%) experienced any AE and 1,968 (82.3%) experienced an AE of interest. This compared to 1,998 (78.0%) of the 2,395 randomized to placebo who experienced any AE and 1,796 (75.0%) who experienced an AE of interest.  The relative rate of an AE of interest (Table 1) was 27% higher for those randomized to MTX (HR 1.27, 95% CI 1.19– 1.35) compared to placebo.  The relative rates of gastrointestinal (HR 1.88, 95% CI 1.71-2.07), infectious (HR 1.16, 95% CI 1.03-1.31), pulmonary (HR 1.41, 95% CI 1.14-1.75), and hematologic (HR 1.17, 95% CI 1.09-1.26) events were elevated for those randomized to MTX.  There was no difference between treatment arms for the risk of malignant, mucocutaneous, neuropsychiatric, musculoskeletal, or renal AEs. While there were no overall differences in malignancies, skin cancers were more common in patients randomized to MTX than placebo, with a composite skin cancer HR 2.20 (95% CI 1.39-3.50) and squamous cell cancer HR 3.55 (95% CI 1.78-7.05) (Table 2).

Conclusion: In this large RCT among patients with known cardiovascular disease, MTX was associated with a significantly increased risk of AEs compared with placebo. While the trial was conducted in non-rheumatic disease patients and only select adverse events were adjudicated, the elevated risks observed for infectious, pulmonary, gastrointestinal, hematologic and skin cancer events represent a broad range of clinical issues, requiring further examination. These results quantify risk of MTX for the many clinicians and patients considering treatment across the spectrum of systemic rheumatic diseases.


Table 1.ACRabstract.solomon


Table 2.ACRabstract.solomon


Disclosure: D. Solomon, AbbVie, 2, Abbvie, 2, Amgen, 2, AstraZeneca, 2, Corrona, 2, Genentech, 2, Janssen, 2, Lilly, 2, Pfizer, 2; R. Glynn, None; E. Karlson, None; F. Lu, None; C. Corrigan, None; J. Colls, None; C. Xu, None; J. MacFadyen, None; M. Barbhaiya, None; N. Berliner, None; P. Dellaripa, Bristol Myers Squibb, 2, Genentech, 2, UpToDate, 7; B. Everett, Amgen, 5, FDA, 5, NIDDK, 5, Novartis, 2, 5, Roche Diagnostics, 2, 5; S. Hammond, None; M. Murray, None; D. Rao, Janssen, 5, Merck, 2, Pfizer, 5; S. Ritter, None; A. Rutherford, None; J. Sparks, None; J. Stratton, None; D. Suh, None; S. Tedeschi, None; K. Vanni, None; N. Paynter, None; P. Ridker, None.

To cite this abstract in AMA style:

Solomon D, Glynn R, Karlson E, Lu F, Corrigan C, Colls J, Xu C, MacFadyen J, Barbhaiya M, Berliner N, Dellaripa P, Everett B, Hammond S, Murray M, Rao D, Ritter S, Rutherford A, Sparks J, Stratton J, Suh D, Tedeschi S, Vanni K, Paynter N, Ridker P. Methotrexate Adverse Events in a Randomized Double-Blind Placebo-Controlled Trial:Results from the Cardiovascular Inflammation Reduction Trial (CIRT) [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/methotrexate-adverse-events-in-a-randomized-double-blind-placebo-controlled-trialresults-from-the-cardiovascular-inflammation-reduction-trial-cirt/. Accessed July 1, 2022.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/methotrexate-adverse-events-in-a-randomized-double-blind-placebo-controlled-trialresults-from-the-cardiovascular-inflammation-reduction-trial-cirt/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies